Coherus Oncology, Inc. (CHRS) is the 383rd largest of 758 Pharmaceuticals and Biotechnology companies by market capitalisation, at 115.85 Mn, behind Akebia Therapeutics at 116.85 Mn. The table below compares all 758 on 7 financial metrics, including companies with a secondary business in the group.
| # | Symbol | Company | Industry | Mkt Cap | Price | Chg % | 1Y | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly | Pharmaceuticals | 1.29 Tn | 1,367.37 | -3.55% | +47.69% | 44.22 | 14.88 | 1.26 Tn |
| 2 | JNJ | Johnson & Johnson | Pharmaceuticals | 655.58 Bn | 272.33 | -1.45% | +46.41% | 40.77 | 6.60 | 575.44 Bn |
| 3 | ABBV | AbbVie | Pharmaceuticals | 509.44 Bn | 288.21 | -2.27% | +32.96% | 49.30 | 7.72 | 477.50 Bn |
| 4 | MRK | Merck | Pharmaceuticals | 362.14 Bn | 146.90 | -2.31% | +74.07% | 147.80 | 5.37 | 325.14 Bn |
| 5 | NVS | Novartis Ag | Pharmaceuticals | 309.04 Bn | 161.96 | -1.81% | +29.05% | 17.91 | 5.08 | 282.62 Bn |
| 6 | AZN | Astrazeneca | Pharmaceuticals | 289.57 Bn | 186.82 | -1.23% | +15.11% | 26.25 | 4.88 | 263.55 Bn |
| 7 | AMGN | Amgen | Biotechnology | 248.97 Bn | 460.28 | -3.80% | +43.90% | 26.52 | 6.40 | 200.62 Bn |
| 8 | GILD | Gilead Sciences | Biotechnology | 207.95 Bn | 167.57 | -3.96% | +36.70% | -53.88 | 6.71 | 182.98 Bn |
| 9 | ABT 2nd | Abbott Laboratories | Generic Drugs | 196.71 Bn | 113.58 | -1.72% | -8.80% | 41.91 | 4.08 | 171.17 Bn |
| 10 | PFE | Pfizer | Pharmaceuticals | 170.25 Bn | 29.87 | -2.99% | +21.37% | 42.22 | 2.68 | 117.91 Bn |
| 11 | VRTX | Vertex Pharmaceuticals | Biotechnology | 137.54 Bn | 542.50 | -1.19% | +30.10% | 34.59 | 10.62 | 109.53 Bn |
| 12 | BMY | Bristol Myers Squibb | Pharmaceuticals | 129.08 Bn | 63.15 | -1.64% | +35.89% | 13.96 | 2.58 | 84.28 Bn |
| 13 | GSK | Gsk | Pharmaceuticals | 108.79 Bn | 50.42 | -1.35% | +7.99% | 8.10 | 1.41 | 91.12 Bn |
| 14 | MRNA | Moderna | Biotechnology | 96.34 Bn | 241.46 | -6.55% | +924.87% | -30.50 | 43.24 | 75.70 Bn |
| 15 | REGN | Regeneron Pharmaceuticals | Biotechnology | 91.82 Bn | 902.90 | -2.98% | +40.16% | 19.06 | 5.43 | 57.17 Bn |
| 16 | TAK | Takeda Pharmaceutical | Pharmaceuticals | 67.47 Bn | 21.20 | +0.62% | +56.00% | 211.54 | 2.25 | 45.69 Bn |
| 17 | COR 2nd | Cencora | Animal Health | 64.86 Bn | 339.89 | -4.00% | -3.99% | 25.01 | 0.19 | 53.95 Bn |
| 18 | SNY | Sanofi | Pharmaceuticals | 57.19 Bn | 46.90 | -1.20% | -4.29% | 6.05 | 1.04 | 27.39 Bn |
| 19 | ARGX | Argenx Se | Biotechnology | 55.37 Bn | 894.70 | -3.94% | +7.49% | 29.22 | 9.51 | 55.37 Bn |
| 20 | IDXX | Idexx Laboratories | Animal Health | 52.85 Bn | 670.71 | -3.99% | -6.87% | 44.72 | 11.33 | 52.07 Bn |
| 21 | TEVA | Teva Pharmaceutical Industries | Generic Drugs | 48.72 Bn | 41.75 | -0.17% | +69.72% | 96.21 | 2.83 | 33.68 Bn |
| 22 | ONC | BeOne Medicines | Pharmaceuticals | 43.77 Bn | 387.25 | +2.51% | +20.49% | 65.89 | 7.14 | 25.29 Bn |
| 23 | RVMD | Revolution Medicines | Pharmaceuticals | 38.42 Bn | 177.65 | -11.04% | +199.38% | -20.41 | 194.50 | 26.90 Bn |
| 24 | GEHC 2nd | GE HealthCare Technologies | Pharmaceuticals | 37.87 Bn | 83.75 | -2.40% | +10.77% | 17.57 | 1.75 | 26.33 Bn |
| 25 | ALC 2nd | Alcon | Pharmaceuticals | 37.31 Bn | 76.55 | -0.98% | +2.97% | 58.72 | 3.46 | 28.28 Bn |
Coherus Oncology, Inc. (CHRS) is compared with 758 US-listed companies in the Pharmaceuticals and Biotechnology industry group, of which 694 have it as their primary business and 64 run a substantial Pharmaceuticals and Biotechnology business alongside something else.
Peers are every company that BQ-MICS, our own multi-industry classification system, places in the same industry group as Coherus Oncology, Inc.. Unlike a single-label scheme, BQ-MICS assigns each company a primary industry and any secondary industries it genuinely operates in, and records the reasoning behind every assignment. Tap the info icon beside any ticker to read it.
It marks a secondary match: the company operates a real business in this industry group, but it is not its largest. Tick "Primary business only" above the table to compare against pure plays alone.
Prices, market caps and valuation figures refresh with each session's close. The classification itself is reviewed whenever a company's filings change what it does, such as a new segment, a disposal or an acquisition.
Yes. Use Edit Columns above the table to add any of 1,000+ financial metrics and ratios to the comparison, and Download Data to export it.
Pull Coherus Oncology, Inc.'s industry peers, with any metrics you choose plus the industry median and average, in one call with the Business Quant Peers API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/peers?ticker=CHRS&cols=Revenue%20(Quarter),Net%20Income%20(Quarter)&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/peers"
params = {"ticker": "CHRS", "cols": "Revenue (Quarter),Net Income (Quarter)", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/peers?ticker=CHRS&cols=Revenue%20(Quarter),Net%20Income%20(Quarter)&api_key=YOUR_API_KEY");
const data = await res.json();